SEC Form 4 · accession 0001780547-26-000004
Janux Therapeutics, Inc. · JANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natasha Hernday
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817713
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | A | 5,500 | $0.00 | A | 15,481 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $13.66 | Jun 11, 2026 | A | 15,500 | A | — | Jun 10, 2036 | Common Stock | 15,500 | 15,500 | D |
Explanation of responses
- F1Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
- F2The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.